Dynavax Technologies | DVAX - Assets


Dynavax Technologies reported $946.51M in Assets for its fiscal quarter ending in September of 2025.



Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Adma Biologics USD 624.24M 55.56M Dec/2025
Agenus USD 226.8M 7.09M Dec/2025
Amgen USD 90.59B 445M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025